Elisabeth Huijbers

Dr. Elisabeth Huijbers

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JBJudy R. van Beijnum
Judy R. van Beijnum
EHElisabeth Huijbers
Elisabeth Huijbers
KLKarlijn van Loon
Karlijn van Loon
ABAthanasios Blanas
Athanasios Blanas
PAParvin Akbari
Parvin Akbari
AGArjan Griffioen
Arjan Griffioen
Anti-angiogenic cancer therapies possess immune-stimulatory properties by counteracting pro-angiogenic molecular mechanisms. We report that tumor endothelial cells ubiquitously overexpress and secrete the intermediate filament protein vimentin through type III unconventional secretion mechanisms. Extracellular vimentin is pro-angiogenic and functionally mimics VEGF action, while concomitantly acting as inhibitor of leukocyte-endothelial interactions. Antibody targeting of extracellular vimentin shows inhibition of angiogenesis in vitro and in vivo. Effective and safe inhibition of angiogenesis and tumor growth in several preclinical and clinical studies is demonstrated using a vaccination strategy against extracellular vimentin. Targeting vimentin induces a pro-inflammatory condition in the tumor, exemplified by induction of the endothelial adhesion molecule ICAM1, suppression of PD-L1, and altered immune cell profiles. Our findings show that extracellular vimentin contributes to immune suppression and functions as a vascular immune checkpoint molecule. Targeting of extracellular vimentin presents therefore an anti-angiogenic immunotherapy strategy against cancer.

14 January 2022 in Science Immunology
Verified
Journal Article
Closed access
EHElisabeth Huijbers
Elisabeth Huijbers
KKKabir A. Khan
Kabir A. Khan
RKRobert S. Kerbel
Robert S. Kerbel
AGArjan Griffioen
Arjan Griffioen
Tumors escape immunity by using embryonic-like angiogenesis resulting in nonadhesive vasculature, preventing leukocyte infiltration.

3 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
DEDiederik JM Engbersen
Diederik JM Engbersen
JBJudy van Beijnum
Judy van Beijnum
ARArno Roos
Arno Roos
MBMarit van Beelen
Marit van Beelen
JHJan David de Haan
Jan David de Haan
EHElisabeth Huijbers
Elisabeth Huijbers
It was recently shown that targeting extracellular vimentin (eVim) is safe and effective in preclinical models. Here, we report the safety and efficacy in client-owned dogs with spontaneous bladder cancer of CVx1, an iBoost technology-based vaccine targeting eVim in combination with COX-2 inhibition. This was a single-arm prospective phase 1/2 study with CVx1 in 20 client-owned dogs with spontaneous UC which involved four subcutaneous vaccinations with CVx1 at 2-week intervals for induction of antibody titers, followed by maintenance vaccinations at 2-month intervals. Additionally, daily cyclooxygenase (COX)-2 inhibition with meloxicam was given. The response was assessed by antibody titers, physical condition, abdominal ultrasound and thorax X-ray. The primary endpoints were the development of antibody titers, as well as overall survival compared to a historical control group receiving carboplatin and COX-2 inhibition with piroxicam. Kaplan–Meier survival analysis was performed. All dogs developed antibodies against eVim. Titers were adequately maintained for the duration of this study. A median overall survival of 374 days was observed, which was 196 days for the historical control group (p < 0.01). Short-term grade 1–2 toxicity at the injection site and some related systemic symptoms peri-vaccination were observed. No toxicity was observed related to the induced antibody response. A limitation of this study is the single-arm prospective setting. CVx1 plus meloxicam consistently induced efficient antibody titers, was well tolerated and showed prolonged survival. The results obtained merit further development for human clinical care.

17 March 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
EHElisabeth Huijbers
Elisabeth Huijbers
JBJudy van Beijnum
Judy van Beijnum
KLKarlijn van Loon
Karlijn van Loon
CGChristian J. Griffioen
Christian J. Griffioen
RVRichard Volckmann
Richard Volckmann
AGArjan Griffioen
Arjan Griffioen
A sustained blood supply is critical for tumor growth, as it delivers the nutrients and oxygen required for development. Targeting of blood vessel formation via immunotherapies is an area of great importance. Knowing that certain embryonic genes, such as carcinoembryonic antigens (CEA) and oncofetal fibronectin, become reexpressed in malignant transformation, we hypothesized that a similar phenomenon holds true for tumor endothelial cells (TECs) as well. An approach for identification of highly selective tumor endothelial markers was conducted to develop targeted antiangiogenic immunotherapies. We first queried the transcriptome that is present during embryo development. We then performed a systematic search for genes selectively expressed in the mouse embryo at days E11 and E18, as compared to the transcriptome of the adult mouse. Subsequently, we queried for expression of these embryonic genes in sorted murine TECs. This approach identified among others the tumor endothelial antigens fibrillin-2 (Fbn2), elastin microfibril interface-located protein 2 (Emilin2) as well as the tumor endothelial antigens lysyl oxidase (Lox) and serine/cysteine protease inhibitor, clade E, member 1 (Serpine1; Pai-1). For these selected genes, functional involvement in angiogenesis was confirmed in in vitro bioassays. We subsequently used iBoost conjugate vaccine technology to develop vaccines against the selected targets. For all four targets, vaccination readily induced target-specific antibody responses in mice, resulting in inhibition of tumor growth. Access to highly specific tumor endothelial markers provides opportunities for direct targeting of the tumor vasculature with high specificity, without affecting healthy vasculature.

24 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
KLKarlijn van Loon
Karlijn van Loon
EHElisabeth Huijbers
Elisabeth Huijbers
JHJan David de Haan
Jan David de Haan
AGArjan Griffioen
Arjan Griffioen
Extracellular vimentin is a specific marker of the tumor vasculature, where it is secreted by tumor endothelial cells. Vaccination with a conjugate vaccine targeting extracellular vimentin was previously shown to induce a potent humoral immune response and tumor growth inhibition in mice. These data were obtained by vaccination using the toxic Freund’s adjuvant (FA) and are therefore not directly translatable into the clinic. In the present study, we aimed to investigate the potential of the biodegradable Montanide ISA 720 adjuvant. We tested Montanide either alone (MN) or supplemented with CpG 1826 (MN-C). Both adjuvant compositions, as well as FA, resulted in a significant tumor growth inhibition and decreased vessel density in the B16F10 melanoma tumor model. Vaccination of mice with either FA or MN-C resulted in an equally potent humoral immune response towards vimentin, while the antibody titers obtained with MN alone were significantly lower compared to FA. Vaccination coincided with the infiltration of immune cells. The highest number of intratumoral immune cells was seen in tumors from the MN-C group. Therefore, we conclude that Montanide ISA 720 supplemented with CpG allows efficient vaccination against extracellular vimentin, which is a prerequisite for the transfer of the vaccine into the clinic.

1 July 2019 in Vaccine
Verified
Journal Article
Open access
EHElisabeth Huijbers
Elisabeth Huijbers
JBJudy van Beijnum
Judy van Beijnum
CLChung T. Lê
Chung T. Lê
SLSophia Langman
Sophia Langman
PNPatrycja Nowak-Sliwinska
Patrycja Nowak-Sliwinska
AGArjan Griffioen
Arjan Griffioen